Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne
Status:
Completed
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene
0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory
hyperpigmentation in subjects with acne.